Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis

NCT03579966 is registered in ClinicalTrials.gov with Catalyst Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03579966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03579966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 11, 2018
Completion date
August 5, 2022
Enrollment
63 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

achr myasthenia gravis, myasthenia gravis, musk